|Daily Range||$22.36 - $24.27|
|52-Week Range||$21.00 - $39.86|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||215,753|
|Current FY EPS||-$3.02|
Revance Therapeutics, Inc (RVNC) Description
Revance Therapeutics, Inc Website: http://www.revance.com/
Sarepta Therapeutics, Revance Therapeutics, and Cytokinetics saw big moves recently; MannKind and Orexigen could be next.
Merger and acquisition deals and rumors were the talk of the town this week, while three additional clinical and filing updates led to double-digit percentage moves.
M&A activity sends the S&P 500 decisively higher as GW Pharmaceuticals, Revance Therapeutics, and Allergan all jump by double digits.
Revance shares are looking good after reporting positive phase 1/2 study data on RT002. Find out what investors should do based on this news.
Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines